Brought to you by 
The Medicines Co., Nycomed in Angiomax agreement
31 Jul 2015
Executive Summary
Nycomed Danmark (private company owned by equity group that manufactures and markets drugs and consumer health products) will exclusively distribute The Medicines Co.'s cardiovascular drug Angiomax (bivalirudin) in 35 countries including 12 in Europe.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
The Medicines Co., Nycomed in Angiomax agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice